By enGenes Biotech…
enGenes Biotech bringing recombinant protein and plasmid DNA advances to World Vaccine Congress
Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech will bring insights on its latest technological advances in enhanced production of plasmid DNA to the World Vaccine Congress in Barcelona.
The enGenes team at WVC 2024 will use the event to share knowledge and data gained from multiple ongoing projects and seek new partners for its patented technology platforms for intracellular and extracellular manufacturing, antibiotic-free systems, and more.
Leading role
Senior enGenes scientists Dr. Natalia Danielewicz and Dr. Karl Hübler are participating in the congress event hoping to network and attract new collaborations for its accelerated expression processes that separate growth and production phases, enable long-term cultivation, and enhance stability.
“We are looking to get into conversations with people in search of new ways to embrace our technologies and adapt them to various vaccine applications,” said Dr. Danielewicz.
The enGenes team will highlight the potential of enGenes -eXcess™ technology to optimize the manufacturing of high-quality plasmid DNA for gene therapy and vaccine development as well as the -eXchange™ platform for antibiotic-free and resistance marker-free manufacturing of recombinant proteins and plasmid DNA. They will also emphasize the influential role of its -eXpress™ and -eXcite™ technologies in the drive towards greener continuous production of biologics, as part of the ECOnti consortium.
New connections
“We are excited to participate in this important congress, share our research, and engage with our peers from across the world. This event is an invaluable opportunity to exchange ideas and foster collaborations that will drive forward the development of new and effective vaccines,” said Dr. Natalia Danielewicz.
“The World Vaccine Congress is a premier event in the field of vaccinology, bringing together experts from around the globe to discuss the latest advancements, challenges, and innovations in vaccine development and immunology. That makes it an ideal platform for creating new connections with various companies and academic institutions Our team is looking forward to contributing to the conversations that will shape the future of global health,” Dr. Danielewicz continued.
“The congress will cover a wide array of topics, from emerging vaccine technologies to the latest clinical trial updates and global immunization efforts. As part of this prestigious gathering, our team aims to bring unique insights into recombinant protein manufacturing and pDNA,” she added.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes- eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
Find out more at: https://www.engenes.cc
About World Vaccine Congress Europe 2024
Billed as Europe’s leading vaccine event, the World Vaccine Congress Europe is the largest and longest-established European meetings on vaccine R&D.
WVC 2024 will be held over four days in Barcelona, beginning with Pre-Congress Workshops on 28 October 2024 at the Catalonia Barcelona Plaza and moving on to the main three-day conference opening October 29 at the Fira de Barcelona in Montjuïc Park.
The 2024 conference theme highlights R&D + Strategic Partnering for the Global Vaccine Industry, with a program covering multiple topics including Clinical Development, Bioprocessing & Manufacturing, and Cancer Immunotherapy. The co-located Exhibition will feature some 150 solutions providers from around the world.
The event is organized by Terrapin with further information at: https://www.terrapinn.com/conference/world-vaccine-congress-europe/index.stm
Resources
Click on LinkedIn for more information about enGenes at WVC and to schedule a meeting with its team at the Congress.